The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Big buys showing up after hours? What do we think?
I’m guessing we should be expecting some RNS’S before the presentations ? Will there be market sensitive information in the presentations?
Are you thinking it’s the American market that’s trying to keep the sp down? What’s they’re motive? Low take over bid from Merck?
Looking good for November then..
Also with COVID 19 vaccines looking further and further away if at all the possible treatment 4D can provide opens up big opportunities..
I’m not going to put a figure on it as metals are the flavour of the week at the moment but with the current situation pharmas will be back on top by Christmas..
Seems like Merck will want the MRx0518 and Keytruda combination pushed through sooner than we think?
Like clockwork at the moment after hours buys,
4D is due a rise and a big one at that..
I’m fully expecting to see some more big after hours buys today. Something tells me someone knows more than us..
Someone has been buying big for the last few days after hours, I would imagine in preparation for the cancer presentation in November..
Excellent post Micheal, very informative.
Lots more buys than sells , market sentiment is bad all over the board today. Any other time we’d be looking at a much bigger rise after yesterday’s RNS’S..
£100k late buy amongst some other big buys.
I would imagine this rns will add 10-15% on the sp over the next week with a gradual climb then as we get closer to the live presentation .
Just my thoughts..
RNS out this morning regarding presentation in November
I think he’s angry the way the market has manipulated the sp this last week, expect some big buys and tr1’s this week.
https://youtu.be/8ojyr5oQToY
A great interview with Duncan
Posted today
Seres Therapeutics $MCRB Reaches New 12-Month High at $33.16
Do we think we could see Merck increase their holding? I’ve just been reading up on the series/nestle deal .